Journal
BIOANALYSIS
Volume 8, Issue 8, Pages 753-764Publisher
FUTURE SCI LTD
DOI: 10.4155/bio-2015-0022
Keywords
antipeptide antibody column; biomarkers; extended SIL peptide; immunoaffinity; LC-MS; method development
Funding
- Pfizer
- Eli Lilly and Co.
- Pfizer, Inc.
Ask authors/readers for more resources
Background: A previously described immunoaffinity (IA)-LC-MS/MS assay for human beta-nerve growth factor (beta-NGF) was implemented to support large-scale sample testing for multiple clinical trials. Methodology & results: The procedure was modified to increase throughput by simultaneous preparation of two 96-well plates and LC duty-cycle reduction. Robustness of the LC method and nano-ESI was ensured during large-scale assay execution by closely monitoring and, if needed, replacing system components prior to failure. Following validation, the assay was used to analyze approximately 19,000 samples from multiple clinical studies over several years. Conclusion: Routine implementation of the beta-NGF IA-LC-MS/MS assay supported drug development programs. This optimized assay format now serves as a template for other clinical protein biomarker assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available